ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Renowned chemical biologist Jay Bradner will leave academia to become president of the Novartis Institutes for BioMedical Research. Bradner, a physician and research scientist at Dana-Farber Cancer Institute and Harvard Medical School, has made significant contributions to cancer research, discovering the first small molecules to block the BET family of bromodomain proteins and, more recently, regulators of gene control called “super-enhancers.” Bradner is the scientific founder of several biotech companies, including Syros Pharmaceuticals and Acetylon Pharmaceuticals. He will replace Mark C. Fishman, who in March will hit his contractual retirement age.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter